“可威”专利倒计时之下的东阳光药

瀚数财经
02 Jul

“可威”之后,东阳光药还有牌可打吗?01太重要的可威东阳光长江药业旗下的“可威”,是目前国内治疗流行性感冒的一线用药,2024年在中国磷酸奥司他韦市场的占有率达到了54.8%,其颗粒剂型更是国内治疗儿童流感的主力品牌之一。对于东阳光长江药业来说,“可威”对业绩的贡献可谓举足轻重。而对拟通过吸收合并东阳光长江药业以介绍形式实现港股上市的控股股东东阳光药而言,这款产品同样至关重要。2024年,“可威”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10